Xilio Therapeutics, Inc. (XLO)
NasdaqCM · USD · Healthcare · Biotechnology
$7.31 (-3.43%) as of
Key statistics
- Market cap
- 48.10M
- Forward P/E
- -12.60
- EPS (TTM)
- -0.62
- Dividend yield
- 0.00%
- 52-week range
- 6.47 – 12.59
- Beta
- -0.12
- Revenue (TTM)
- 64.09M
- Profit margin
- -34.06%
- Analyst target
- $18.00
- Volume
- 33.07k
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Waltham, MA, United States
- Employees
- 76
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.